Mylan
-
Gilead licenses remdesivir for Covid-19 to generic companies for sale in 127 countries
Five generic companies will have the right to manufacture and sell generic versions of the drug in mostly lower-income countries, as well as higher-income countries that face “significant obstacles” to healthcare access.
-
Biopharma companies face regulatory, deal delays due to Covid-19
Intercept Pharmaceuticals and bluebird bio said they had encountered regulatory snags at the FDA for their investigational drugs, while Pfizer is pausing most of its clinical trials and delaying completion of a deal with Mylan to create a new company.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Geopolitical, economic concerns unlikely to stem pharma, life science industry capital deployment, report finds
Deal value for the third quarter fell sharply from what it was in the first and second quarter, but that was due to the absence of the large acquisitions that took place earlier this year rather than an overall downward trend.
-
Mylan, Pfizer’s Upjohn to combine into new company
The new firm, currently known only as “NewCo,” will be rebranded at the deal’s close. In connection with the agreement, Mylan’s CEO since 2012, Heather Bresch, plans to retire from her position.
-
Allergan, Saint Regis Mohawk Tribe ask SCOTUS to hear Restasis patent case
A federal court last year put the kibosh on a deal whereby Allergan transferred to the tribe the Restasis patents, which the tribe then licensed back to Allergan, asserting tribal sovereign immunity to have generic companies’ challenge to the patents dismissed.
-
EpiPen, often chided for high price, gets first generic competitor
The drugmaker’s generic had originally met with FDA rejection in early 2016, amid a national debate over EpiPen’s price.
-
Biosimilars market set to nearly quadruple in next five years, report finds
Market forecast rosy, though market in United States remains young.
-
Wanted: Generic competition
FDA has announced two more initiatives designed to foster greater generics competition, a key priority for new commissioner Scott Gottlieb.
-
Why did Mylan invest in coal plants?
Mylan evidently subscribes to a “living in the gray” mentality when it comes to business operations.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Is Mylan’s EpiPen reign finally over?
A healthy dose of competition has been injected into the market for life-saving emergency epinephrine injectors.
-
BioPharma, Payers, Pharma, Policy
Investigation into drug price hikes yields first lawsuit
Attorneys general in 20 states have filed an anti-trust lawsuit against Heritage, Mylan, Teva and three other generic drug companies, alleging price-fixing and market-splitting tactics between the competition.
-
Mylan settles EpiPen Medicaid rebate case for $465M, stock jumps
Mylan settled with the U.S. Department of Justice to head off potential Medicaid liability claims by federal and state governments.
-
Runaway cost of EpiPens hits taxpayers right in their Medicare
The abrupt rise is notable because many people think that life-threatening allergies are less common among the elderly. In addition, epinephrine — the active ingredient in EpiPens — can pose greater risks to older adults.
-
How Mylan cornered the consumer epinephrine market
High-profile deaths in several states have helped to spur legislative action and fuel demand for consumer-dispensed epinephrine. At the same time, no other company has been able to effectively compete with Mylan’s EpiPen.
-
Now, the gloves are off in the EpiPen saga
The maker of EpiPen, the life-saving auto-injector for anaphylaxis, is under fire for exorbitant price hikes so much so that even Martin Shkreli called Mylan out for price-gouging last week.